Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.

Niu, Man Man; Cao, Yue; Li, Rui Xue; Fan, Guo Zhen; Hu, Peng

Niu, Man Man; Cao, Yue; Li, Rui Xue; Fan, Guo Zhen; Hu, Peng.

Niu MM; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Cao Y; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Li RX; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Fan GZ; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hu P; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.

Clin Infect Dis ; 74(8): 1504, 2022 04 28.

Article in English | MEDLINE | ID: covidwho-1702966

Subject(s)

COVID-19 Drug Treatment; Antibodies, Monoclonal, Humanized/therapeutic use; Humans; SARS-CoV-2; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google